AU726158B2 - Small and intermediate conductance, calcium-activated potassium channels and uses thereof - Google Patents

Small and intermediate conductance, calcium-activated potassium channels and uses thereof Download PDF

Info

Publication number
AU726158B2
AU726158B2 AU42660/97A AU4266097A AU726158B2 AU 726158 B2 AU726158 B2 AU 726158B2 AU 42660/97 A AU42660/97 A AU 42660/97A AU 4266097 A AU4266097 A AU 4266097A AU 726158 B2 AU726158 B2 AU 726158B2
Authority
AU
Australia
Prior art keywords
seq
protein
nucleic acid
leu
calcium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU42660/97A
Other languages
English (en)
Other versions
AU4266097A (en
Inventor
John P. Adelman
Chris T. Bond
James Maylie
Christopher P. Silvia
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oregon Health & Science University
Icagen Inc
Original Assignee
Oregon Health & Science University
Icagen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oregon Health & Science University, Icagen Inc filed Critical Oregon Health & Science University
Publication of AU4266097A publication Critical patent/AU4266097A/en
Application granted granted Critical
Publication of AU726158B2 publication Critical patent/AU726158B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • General Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
AU42660/97A 1996-09-11 1997-09-10 Small and intermediate conductance, calcium-activated potassium channels and uses thereof Ceased AU726158B2 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US2645196P 1996-09-11 1996-09-11
US60/026451 1996-09-11
US4005297P 1997-03-07 1997-03-07
US60/040052 1997-03-07
US4523397P 1997-04-17 1997-04-17
US60/045233 1997-04-17
PCT/US1997/016033 WO1998011139A1 (en) 1996-09-11 1997-09-10 Small and intermediate conductance, calcium-activated potassium channels and uses thereof

Publications (2)

Publication Number Publication Date
AU4266097A AU4266097A (en) 1998-04-02
AU726158B2 true AU726158B2 (en) 2000-11-02

Family

ID=27362774

Family Applications (1)

Application Number Title Priority Date Filing Date
AU42660/97A Ceased AU726158B2 (en) 1996-09-11 1997-09-10 Small and intermediate conductance, calcium-activated potassium channels and uses thereof

Country Status (8)

Country Link
US (9) US6797486B2 (enExample)
EP (1) EP0948542B1 (enExample)
JP (5) JP4052525B2 (enExample)
AT (1) ATE366260T1 (enExample)
AU (1) AU726158B2 (enExample)
CA (1) CA2265485C (enExample)
DE (2) DE69739956D1 (enExample)
WO (1) WO1998011139A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1012281B1 (en) * 1997-07-15 2006-11-29 AstraZeneca UK Limited Human leukocyte calcium activated potassium channel polypeptide
US6165719A (en) * 1997-07-15 2000-12-26 The Regents Of The University Of California hKCa3/KCNN3 small conductance calcium activated potassium channel: a diagnostic marker and therapeutic target
AU2001265384A1 (en) 2000-06-06 2001-12-17 Millennium Pharmaceuticals, Inc. 52906, 33408, and 12189, potassium channel family members and uses thereof
EP1345618B1 (de) * 2000-12-28 2005-03-23 Switch Biotech Aktiengesellschaft Chlorzoxazon zur behandlung von psoriasis
US7022480B1 (en) * 2001-10-11 2006-04-04 The Regents Of The University Of California Exons of the hSKCa3/KCNN3 gene
US20050250090A1 (en) * 2003-10-28 2005-11-10 Edward Kaftan Assay systems and methods for detecting molecules that interact with SK2 channels
EP1884774A1 (en) * 2006-08-03 2008-02-06 INSERM (Institut National de la Santé et de la Recherche Medicale) A method for the in vitro screening of anti-cancer compounds that inhibits SK3 activity, and said anti-cancer compounds
CN110378549B (zh) * 2019-05-31 2023-05-23 广东工业大学 一种基于fahp-熵权法的输电杆塔鸟害等级评估方法
CN121057823A (zh) * 2023-04-10 2025-12-02 耶鲁大学 体内修饰神经元以治疗和/或预防肌萎缩性侧索硬化(als)的方法
WO2025175135A1 (en) * 2024-02-15 2025-08-21 Yale University Modifying neurons to treat or prevent parkinson's disease

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989009791A1 (en) * 1988-04-14 1989-10-19 University Of North Carolina At Chapel Hill Dna encoding androgen receptor protein

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT392957B (de) 1987-08-06 1991-07-25 Technoagrar Consulting Ag Verfahren zur behandlung und entsorgung von gemengen aus feststoffen und fluessigkeiten
CA2116280A1 (en) * 1993-03-05 1994-09-06 Marcy E. Macdonald Huntingtin dna, protein and uses thereof
US5519003A (en) 1994-02-01 1996-05-21 Board Of Trustees Of The Leland Stanford Junior University WD-40-derived peptides and uses thereof
US6277978B1 (en) * 1995-12-22 2001-08-21 University Of Utah Research Foundation KVLQT1—a long QT syndrome gene
EP1012281B1 (en) 1997-07-15 2006-11-29 AstraZeneca UK Limited Human leukocyte calcium activated potassium channel polypeptide
US6165719A (en) * 1997-07-15 2000-12-26 The Regents Of The University Of California hKCa3/KCNN3 small conductance calcium activated potassium channel: a diagnostic marker and therapeutic target
WO1999025347A2 (en) 1997-11-14 1999-05-27 Neurosearch A/S Chemical compounds having ion channel blocking activity for the treatment of immune dysfunction

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989009791A1 (en) * 1988-04-14 1989-10-19 University Of North Carolina At Chapel Hill Dna encoding androgen receptor protein

Also Published As

Publication number Publication date
US6828420B2 (en) 2004-12-07
US6828122B2 (en) 2004-12-07
EP0948542B1 (en) 2007-07-04
JP2004024268A (ja) 2004-01-29
DE69737889D1 (de) 2007-08-16
AU4266097A (en) 1998-04-02
JP2006320333A (ja) 2006-11-30
CA2265485A1 (en) 1998-03-19
EP0948542A4 (en) 2004-04-14
US7026451B2 (en) 2006-04-11
DE69737889T2 (de) 2008-03-13
US20020155531A1 (en) 2002-10-24
WO1998011139A1 (en) 1998-03-19
US20020165379A1 (en) 2002-11-07
US20030082684A1 (en) 2003-05-01
US20030082683A1 (en) 2003-05-01
JP4052525B2 (ja) 2008-02-27
US7534869B2 (en) 2009-05-19
US20050214845A1 (en) 2005-09-29
US20030105284A1 (en) 2003-06-05
US6894147B2 (en) 2005-05-17
EP0948542A1 (en) 1999-10-13
CA2265485C (en) 2006-08-01
US6828123B2 (en) 2004-12-07
JP2008092950A (ja) 2008-04-24
US6987169B2 (en) 2006-01-17
JP4052582B2 (ja) 2008-02-27
JP2000514310A (ja) 2000-10-31
US20020192757A1 (en) 2002-12-19
US6692937B2 (en) 2004-02-17
US20030044910A1 (en) 2003-03-06
DE69739956D1 (de) 2010-09-16
JP2004065264A (ja) 2004-03-04
US20030040048A1 (en) 2003-02-27
ATE366260T1 (de) 2007-07-15
US6797486B2 (en) 2004-09-28

Similar Documents

Publication Publication Date Title
JP2008092950A (ja) 低及び中間コンダクタンスのカルシウム活性化されたカリウムチャネル及びその使用
Hruz et al. Cysteine-scanning mutagenesis of transmembrane segment 7 of the GLUT1 glucose transporter
Giangiacomo et al. Molecular basis of α-KTx specificity
US6815539B1 (en) PH sensitive potassium channel in spermatocytes
EP1892252B1 (en) Intermediate conductance, calcium-activated potassium channels and uses thereof
WO1999020754A1 (en) A ph sensitive potassium channel in spermatocytes
JP2004528004A (ja) Ｃｎｇ２ｂ：新規ヒト環状ヌクレオチド作動性イオンチャンネル
GB2372503A (en) Voltage-gated potassium channel polypeptides
Chokvithaya Functional studies of p. N258K and p. G279D variants in the KCNQ2 gene
WO1998033905A1 (en) K-atp channels, materials and methods relating to cell membrane proteins
Ng Molecular mechanism of cyclic nucleotide action on HCN pacemaker channels
JP2003169677A (ja) ドーパ受容体
Rezazadeh-Roudsari Structural and genetic modulators of voltage-gated potassium channel activation kinetics
Gangloff et al. cytokine receptors, Toll has been found to form low-affinity dimers with a dissociation constant of 2 mM in the absence of ligand. In the presence of Spz C-106, it is predominantly foundsignature molecules, ranging from lipopolysaccharide (LPS) for TLR4; lipopeptides for TLRs 2, 1, and 6; nucleic acids for TLRs 3, 7, 8, and 9; and flagella protein for TLR5 (Gay and Gangloff
GB2382576A (en) Voltage-gated ion channel
Leettola A Sterile Alpha Motif Domain Network Involved in Kidney Development

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)